S&P Futures
3,769.75+4.25(+0.11%)Dow Futures
30,926.00+48.00(+0.16%)Nasdaq Futures
12,450.00-5.00(-0.04%)
143.50 -0.50 (-0.35%)
Pre-Market: 4:31AM EST
Chart Events
Performance Outlook
| Previous Close | 149.32 |
| Open | 148.61 |
| Bid | 0.00 x 900 |
| Ask | 147.02 x 800 |
| Day's Range | 142.22 - 149.00 |
| 52 Week Range | 90.14 - 176.64 |
| Volume | 6,033,551 |
| Avg. Volume | 1,826,322 |
| Market Cap | 68.446B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | 42.11 |
| EPS (TTM) | 3.42 |
| Earnings Date | May 04, 2021 - May 10, 2021 |
| Forward Dividend & Yield | 1.00 (0.67%) |
| Ex-Dividend Date | Apr 20, 2021 |
| 1y Target Est | 188.14 |
Fair Value
Related Research
- Zacks
USNA or ZTS: Which Is the Better Value Stock Right Now?
USNA vs. ZTS: Which Stock Is the Better Value Option?
- Business Wire
Zoetis to Participate in the Cowen 41st Annual Health Care Conference
Zoetis will participate in the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021.
- SmarterAnalyst
Zoetis’ Osteoarthritis Therapy For Cats Authorized In Europe; Street Sees 26% Upside
Zoetis Inc., an animal health company announced that Solensia, its treatment of osteoarthritis, has been granted marketing authorization from the European Commission. Specifically, Zoetis’ (ZTS) Solensia is developed as a therapy to relieve osteoarthritis pain in cats. Osteoarthritis has a high prevalence rate in cats affecting about 40%. It can generate pain and may reduce quality of life if gone untreated. Catherine Knupp, EVP and R&D President at Zoetis said, “At Zoetis, our monoclonal antibody research continues to advance the care of animals and our platform allows us to explore new therapeutic areas for the management of diseases with high prevalence and high unmet needs.” Solensia is differentiated from present treatment alternatives on the market by targeting nerve growth factor. The treatment has a monthly frequency and is administered by a veterinarian via an injection. The animal health company commented that 76% of cat owners noted continued improvement in signs of pain upon treating their pets with Solensia . (See Zoetis stock analysis on TipRanks) On Feb. 17 Credit Suisse analyst Erin Wright lifted the price target on Zoetis stock to $203 (27% upside potential) from $197 and reiterated a Buy rating. Wright also raised the 2021 earnings forecast to $4.41 “reflecting stronger revenue growth, partially offset by lower operating margin expansion, reflecting previously expected headwinds related to Draxxin competition and commercial initiatives.” Draxxin is an antibiotic used for treating pneumonia in cattle. The rest of the Street has a Moderate Buy consensus rating on the stock based on 2 Buys and 1 Hold. The average analyst price target of $201.50 implies about 26% upside potential from current levels. The stock has gained about 11% over the past year. Related News: Uber Suffers Blow As UK Court Says Drivers Entitled To Worker Rights – Report IBM Looking To Sell Watson Health Business Unit – Report Novavax Inks Gavi Supply Agreement For 1.1B COVID-19 Vaccine Doses More recent articles from Smarter Analyst: Keysight Tech Quarterly Sales Beat Analysts’ Estimates; Street Says Buy Matador Resources Initiates Quarterly Dividend; Shares Climb 3.5% Dish Network’s 4Q Sales Rise On Higher ARPU; Street Says Hold Rackspace’s 4Q Sales Outperform On Cloud Demand; Guidance Disappoints
